Enliven Therapeutics
ELVN
134 hedge funds and large institutions have $1.22B invested in Enliven Therapeutics in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 32 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
84% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 32
8% more funds holding
Funds holding: 124 → 134 (+10)
2% more capital invested
Capital invested by funds: $1.19B → $1.22B (+$23.4M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20.85% less ownership
Funds ownership: 121.12% → 100.28% (-21%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$18.3M |
| 2 |
BlackRock
New York
|
+$11.1M |
| 3 |
DFO
Duquesne Family Office
New York
|
+$9.76M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$8.68M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$6.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$16.1M |
| 3 |
VA
VR Adviser
New York
|
-$16.1M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$9.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.68M |
ELVN Hedge Fund Activity: Q3 2025 in Review
134 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2025, worth a combined $1.22B — up 2% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ELVN positions and 10 closed out — a net gain of 10 holders — while 59 added to existing stakes and 32 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $18.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $17M sold.
- 134 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2025, up from 124 in Q2 2025.
- Funds reported $1.22B of Enliven Therapeutics stock for Q3 2025, up 2% quarter-over-quarter.
- 20 funds opened new Enliven Therapeutics positions in Q3 2025 and 10 closed out, a net change of +10 holders.
- The largest Enliven Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $18.3M added.
- The largest Enliven Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2025.